What will (and should) be improved in CAR immunotherapy?

Authors: González-Navarro, Europa Azucena, Español, Marta, Egri, Natalia, Castellà, Maria, Calderón, Hugo, España, Carolina, Guijarro, Carla, Heredia, Libertad, Pascal, Mariona, Otero, Manel Juan

Source: International review of cell and molecular biology. 370:149-162

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN630290409&indx=1&recIds=ETOCRN630290409

Chapter Five - What will (and should) be improved in CAR immunotherapy?

Authors: González-Navarro, Europa Azucena, Español, Marta, Egri, Natalia, Castellà, Maria, Calderón, Hugo, España, Carolina, Guijarro, Carla, Heredia, Libertad, Pascal, Mariona, Juan Otero, Manel ^*

Source: In International Review of Cell and Molecular Biology 2022 370:149-161

Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals.

Authors: Ortiz de Landazuri, Iñaki, Egri, Natalia, Muñoz-Sánchez, Guillermo, Ortiz-Maldonado, Valentín, Bolaño, Victor, Guijarro, Carla, Pascal, Mariona, Juan, Manel

Source: Frontiers in Immunology; 10/15/2020, Vol. 11, pN.PAG-N.PAG, 7p

Subject Terms: COVID-19, COVID-19 pandemic, CYTOKINE release syndrome, PRODUCTION management (Manufacturing)

This result is not displayed to guests.
Login for full access.